A phase II trial of CapeOX plus nivolumab for early relapsed HER2-negative gastric cancer (JACCRO GC-11: FirSTAR trial).

MLA

Arai, Hiroyuki, et al. “A Phase II Trial of CapeOX plus Nivolumab for Early Relapsed HER2-Negative Gastric Cancer (JACCRO GC-11: FirSTAR Trial).” Journal of Clinical Oncology, vol. 42, Jan. 2024, p. TPS423. EBSCOhost, https://doi.org/10.1200/JCO.2024.42.3_suppl.TPS423.

APA

Arai, H., Inoue, E., Terashima, M., Baba, E., Matsuhashi, N., Muro, K., Yamaguchi, T., Yuki, S., Ichikawa, W., Fujii, M., & Sunakawa, Y. (2024). A phase II trial of CapeOX plus nivolumab for early relapsed HER2-negative gastric cancer (JACCRO GC-11: FirSTAR trial). Journal of Clinical Oncology, 42, TPS423. https://doi.org/10.1200/JCO.2024.42.3_suppl.TPS423

Chicago

Arai, Hiroyuki, Eisuke Inoue, Masanori Terashima, Eishi Baba, Nobuhisa Matsuhashi, Kei Muro, Toshifumi Yamaguchi, et al. 2024. “A Phase II Trial of CapeOX plus Nivolumab for Early Relapsed HER2-Negative Gastric Cancer (JACCRO GC-11: FirSTAR Trial).” Journal of Clinical Oncology 42 (January): TPS423. doi:10.1200/JCO.2024.42.3_suppl.TPS423.